B. Riley Estimates Agenus' FY2029 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN - Free Report) - B. Riley raised their FY2029 earnings estimates for shares of Agenus in a research report issued to clients and investors on Monday, April 21st. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will earn $0.38 per share for the year, up from their prior estimate of $0.29. B. Riley has a "Buy" rating on the stock. The consensus estimate for Agenus' current full-year earnings is ($12.55) per share.

Agenus (NASDAQ:AGEN - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.36) by $0.32. The company had revenue of $26.84 million for the quarter, compared to the consensus estimate of $30.09 million.

A number of other analysts have also recently commented on AGEN. StockNews.com upgraded shares of Agenus from a "sell" rating to a "hold" rating in a research note on Friday, March 21st. Robert W. Baird dropped their target price on Agenus from $6.00 to $3.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 12th. Finally, HC Wainwright reiterated a "neutral" rating on shares of Agenus in a research report on Tuesday, March 18th. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $8.75.

Agenus Price Performance

Shares of Agenus stock opened at $2.87 on Wednesday. The firm has a market cap of $72.64 million, a PE ratio of -0.26 and a beta of 1.58. Agenus has a 1 year low of $1.38 and a 1 year high of $19.69. The stock has a fifty day moving average price of $2.18 and a 200-day moving average price of $3.07.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Corton Capital Inc. bought a new stake in Agenus in the 4th quarter valued at $36,000. Virtu Financial LLC bought a new stake in shares of Agenus in the fourth quarter worth about $51,000. Apollon Wealth Management LLC purchased a new stake in shares of Agenus in the fourth quarter worth about $55,000. HighTower Advisors LLC boosted its stake in Agenus by 46.1% during the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company's stock valued at $122,000 after buying an additional 7,530 shares during the last quarter. Finally, Bank of Montreal Can purchased a new position in Agenus during the 4th quarter valued at approximately $69,000. 61.46% of the stock is currently owned by institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.